Want to see TSE:SONA full AI Analyst Report?
SONA Stock Chart & Stats
C$0.36
C$0.01(4.84%)
At close: 4:00 PM EDT
C$0.36
C$0.01(4.84%)
Day’s Range― - ―
52-Week RangeC$0.26 - C$0.84
Previous CloseN/A
Volume13.05K
Average Volume (3M)43.49K
Market Cap
C$34.38M
Enterprise ValueC$32.35M
Total Cash (Recent Filing)C$17.21K
Total Debt (Recent Filing)C$340.16K
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Mar 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding122,798,620
10 Day Avg. Volume67,813
30 Day Avg. Volume43,486
Financial Highlights & Ratios
PEG Ratio-2.89
Price to Book (P/B)-1.80K
Price to Sales (P/S)0.00
P/FCF Ratio-35.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Diagnostic NanotechnologySona’s proprietary gold nanorod platform targets a specific performance advantage over traditional gold nanoparticles in diagnostic assays. If validated and commercialized, improved sensitivity could support adoption across lateral-flow, immunoassay, and research-use applications, creating a differentiated technology base.
Reduced Cash BurnThe substantial reduction in operating cash burn indicates progress in controlling cash outflows, even though cash generation remains negative. Lower burn can extend financial runway and provide more time to develop, validate, and commercialize the nanorod platform before additional funding is required.
Modest Absolute DebtDebt is modest in absolute dollars, which limits the direct burden of interest and scheduled repayment obligations. This gives Sona more flexibility than a highly leveraged company to prioritize research, product development, and commercialization efforts, provided it can address its broader capital constraints.
Bears Say
No Revenue GenerationZero reported revenue indicates that Sona has not yet demonstrated commercial monetization of its technology. Without product or licensing revenue, the business remains dependent on funding and future commercialization success, making revenue conversion a major fundamental hurdle over the coming quarters.
Persistent Losses And Negative ProfitabilityRecurring operating and net losses show that the current business model is not yet economically self-sustaining. Although losses have improved from earlier periods, continued unprofitability limits internally funded investment and increases the importance of achieving meaningful sales or commercialization payments.
Deteriorating Balance SheetNegative equity combined with a sharply smaller asset base signals weakened financial resilience despite low nominal debt. This deterioration can restrict strategic flexibility, reduce the resources available for development, and increase reliance on external capital to sustain operations and pursue commercialization.
Sona Nanotech Inc News
SONA FAQ
What was Sona Nanotech Inc’s price range in the past 12 months?
Sona Nanotech Inc lowest stock price was C$0.26 and its highest was C$0.84 in the past 12 months.
What is Sona Nanotech Inc’s market cap?
Sona Nanotech Inc’s market cap is C$34.38M.
When is Sona Nanotech Inc’s upcoming earnings report date?
Sona Nanotech Inc’s upcoming earnings report date is Mar 01, 2027 which is in 132 days.
How were Sona Nanotech Inc’s earnings last quarter?
Sona Nanotech Inc released its earnings results on Sep 25, 2026. The company reported -C$0.01 earnings per share for the quarter.
Is Sona Nanotech Inc overvalued?
According to Wall Street analysts Sona Nanotech Inc’s price is currently Overvalued.
Does Sona Nanotech Inc pay dividends?
Sona Nanotech Inc does not currently pay dividends.
What is Sona Nanotech Inc’s EPS estimate?
Sona Nanotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sona Nanotech Inc have?
Sona Nanotech Inc has 122,798,620 shares outstanding.
What happened to Sona Nanotech Inc’s price movement after its last earnings report?
Sona Nanotech Inc reported an EPS of -C$0.01 in its last earnings report. Following the earnings report the stock price went down -1.493%.
Which hedge fund is a major shareholder of Sona Nanotech Inc?
Currently, no hedge funds are holding shares in TSE:SONA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sona Nanotech Inc
Based in Halifax, Canada, Sona Nanotech Inc. is a life sciences company focused on nanotechnology. It develops and commercializes gold nanorod solutions primarily for diagnostic applications. Their product portfolio includes the Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic test designed to detect the SARS-CoV-2 spike protein antigen in saliva from individuals suspected of having the virus. The company also offers Gemini and Omni gold nanorods, with the latter specifically engineered for medical uses, in addition to providing contract services. These versatile products are utilized in a wide array of applications, such as targeted drug delivery, environmental and food safety monitoring, cellular visualization, cancer therapy, liposuction treatments, and diagnostic tools for medical, consumer, military, and veterinary sectors.
Technical Analysis
BioMark Diagnostics
―
Eastwood Bio-Medical Canada
―
StageZero Life Sciences Ltd
―
Medmira
―
ZYUS Life Sciences
―